BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coccia E, Ahfeldt T. Towards physiologically relevant human pluripotent stem cell (hPSC) models of Parkinson's disease. Stem Cell Res Ther 2021;12:253. [PMID: 33926571 DOI: 10.1186/s13287-021-02326-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Fortune AJ, Fletcher JL, Blackburn NB, Young KM. Using MS induced pluripotent stem cells to investigate MS aetiology. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103839] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Grivennikov IA, Tarantul VZ. Genome Editing Technology for the Study and Correction of Neurodegenerative Diseases. Neurochem J 2021;15:339-52. [DOI: 10.1134/s181971242104005x] [Reference Citation Analysis]
3 Schilder BM, Navarro E, Raj T. Multi-omic insights into Parkinson's Disease: From genetic associations to functional mechanisms. Neurobiol Dis 2021;163:105580. [PMID: 34871738 DOI: 10.1016/j.nbd.2021.105580] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
4 Parga JA, Rodriguez-Perez AI, Garcia-Garrote M, Rodriguez-Pallares J, Labandeira-Garcia JL. NRF2 Activation and Downstream Effects: Focus on Parkinson's Disease and Brain Angiotensin. Antioxidants (Basel) 2021;10:1649. [PMID: 34829520 DOI: 10.3390/antiox10111649] [Reference Citation Analysis]
5 Salmina AB, Kapkaeva MR, Vetchinova AS, Illarioshkin SN. Novel Approaches Used to Examine and Control Neurogenesis in Parkinson's Disease. Int J Mol Sci 2021;22:9608. [PMID: 34502516 DOI: 10.3390/ijms22179608] [Reference Citation Analysis]
6 Arango D, Bittar A, Esmeral NP, Ocasión C, Muñoz-Camargo C, Cruz JC, Reyes LH, Bloch NI. Understanding the Potential of Genome Editing in Parkinson's Disease. Int J Mol Sci 2021;22:9241. [PMID: 34502143 DOI: 10.3390/ijms22179241] [Reference Citation Analysis]